Dr Reddy's Laboratories Ltd-ADR
Closed
SectorHealthcare
13.61 0.81
Overview
Share price change
24h
Min
13.49
Max
13.81
Income | -2.4B 12B |
|---|---|
Sales | -783M 87B |
P/E Sector Avg | 18.25 51.415 |
Dividend yield | 0.7 |
Profit margin | 13.633 |
Employees | 27,811 |
EBITDA | -4.7B 20B |
Dividend yield Sector Avg | 0.70% 2.34% |
|---|
Market Cap | 209M 11B |
|---|---|
Previous open | 12.8 |
Previous close | 13.61 |
News Sentiment
By Acuity
50%
50%
155 / 345 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Dr Reddy's Laboratories Ltd-ADR Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Dr Reddy's Laboratories Ltd-ADR Forecast
Sentiment
By Acuity
155 / 345 Ranking in Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Dr Reddy's Laboratories Ltd-ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.